# Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

> **NCT07222878** · PHASE1 · COMPLETED · sponsor: **NeuroPro Therapeutics, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Epilepsy
- Alzheimer Disease
- Epilepsy Intractable

## Interventions

- **DRUG:** NPT 2042 (Reference formula/Formulation 1)
- **DRUG:** NPT 2042 (Test formula/Formulation 2)
- **DRUG:** NPT 2042 (Test formula/Formulation 2)

## Key facts

- **NCT ID:** NCT07222878
- **Lead sponsor:** NeuroPro Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-29
- **Primary completion:** 2025-11-04
- **Final completion:** 2025-11-04
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07222878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07222878, "Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07222878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*